Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 75
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
2.
Nat Chem Biol ; 20(6): 657, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38773333
3.
Nat Chem Biol ; 20(5): 541, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38671225
4.
Nat Chem Biol ; 20(4): 393, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38528121
5.
Nat Chem Biol ; 20(2): 131, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38267670
6.
Nat Chem Biol ; 20(1): 3, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-38102407
8.
Nat Chem Biol ; 19(11): 1291, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37848546
9.
Nat Chem Biol ; 19(12): 1561, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37872403
11.
Nat Chem Biol ; 19(9): 1043, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37620434
12.
BMC Nephrol ; 24(1): 214, 2023 07 18.
Artigo em Inglês | MEDLINE | ID: mdl-37464309

RESUMO

Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse events with the administration of rituximab. We herein report two cases of symptomatic hypokalemia after intravenous rituximab administration in our center, to help health professionals consider the possibility of acute hypokalemia after rituximab administration, monitor potassium timely and develop an appropriate treatment plan.


Assuntos
Antineoplásicos , Hipopotassemia , Síndrome Nefrótica , Humanos , Rituximab/uso terapêutico , Hipopotassemia/induzido quimicamente , Anticorpos Monoclonais , Antineoplásicos/uso terapêutico
13.
Nat Chem Biol ; 19(8): 921, 2023 08.
Artigo em Inglês | MEDLINE | ID: mdl-37500897
14.
Nat Chem Biol ; 19(7): 791, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-37369869
15.
World J Diabetes ; 14(5): 460-480, 2023 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-37273258

RESUMO

The incidence of diabetic kidney disease (DKD) is sharply increasing worldwide. Microalbuminuria is the primary clinical marker used to identify DKD, and its initiating step in diabetes is glomerular endothelial cell dysfunction, particularly glycocalyx impairment. The glycocalyx found on the surface of glomerular endothelial cells, is a dynamic hydrated layer structure composed of pro-teoglycans, glycoproteins, and some adsorbed soluble components. It reinforces the negative charge barrier, transduces the shear stress, and mediates the interaction of blood corpuscles and podocytes with endothelial cells. In the high-glucose environment of diabetes, excessive reactive oxygen species and proinflammatory cytokines can damage the endothelial glycocalyx (EG) both directly and indirectly, which induces the production of microalbuminuria. Further research is required to elucidate the role of the podocyte glycocalyx, which may, together with endothelial cells, form a line of defense against albumin filtration. Interestingly, recent research has confirmed that the negative charge barrier function of the glycocalyx found in the glomerular basement membrane and its repulsion effect on albumin is limited. Therefore, to improve the early diagnosis and treatment of DKD, the potential mechanisms of EG degradation must be analyzed and more responsive and controllable targets must be explored. The content of this review will provide insights for future research.

16.
Nat Chem Biol ; 19(6): 664, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37253827
17.
Nat Chem Biol ; 19(5): 536, 2023 May.
Artigo em Inglês | MEDLINE | ID: mdl-37117923
18.
Nat Chem Biol ; 19(4): 391, 2023 04.
Artigo em Inglês | MEDLINE | ID: mdl-36991164
19.
Nat Chem Biol ; 19(3): 252, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36854743
20.
Nat Chem Biol ; 19(2): 123, 2023 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-36721019
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA